Tiziana Life Sciences (TLSA) Ratios
Tiziana Life Sciences Ratios
TLSA's free cash flow for Q2 2026 was $-7.42M. For the 2026 fiscal year, TLSA's free cash flow was decreased by $-60.00K and operating cash flow was $-7.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.76 | 1.02 | 1.12 | 3.64 | 6.45 |
| Quick Ratio | 0.76 | 1.02 | 1.12 | 3.64 | 6.45 |
| Cash Ratio | 0.36 | 0.51 | 0.18 | 2.72 | 5.59 |
| Solvency Ratio | -1.59 | -1.60 | -2.65 | -2.22 | -3.08 |
| Operating Cash Flow Ratio | -1.15 | -0.17 | -1.90 | -2.40 | -2.14 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -90.02 | -131.07 | -11.91 |
| Net Current Asset Value | $ -2.89M | $ 160.00K | $ 689.00K | $ 17.38M | $ 41.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.01 | 0.02 | 0.01 | 0.03 |
| Debt-to-Equity Ratio | 8.77 | 0.03 | 0.04 | 0.02 | 0.03 |
| Debt-to-Capital Ratio | 0.90 | 0.03 | 0.04 | 0.02 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 221.06 | 2.87 | 2.20 | 1.35 | 1.18 |
| Debt Service Coverage Ratio | -1009.94 | -1955.50 | -118.82 | -118.91 | -15.09 |
| Interest Coverage Ratio | -1174.00 | -2632.33 | -1798.40 | -2083.71 | -155.53 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Net Debt to EBITDA | 0.20 | 0.22 | 0.05 | 1.16 | 1.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 70.84% | 102.60% | 100.00% | 87.85% |
| EBT Per EBIT | 87.22% | 106.03% | 95.87% | 105.56% | 97.38% |
| Return on Assets (ROA) | -160.34% | -105.13% | -145.20% | -58.15% | -47.96% |
| Return on Equity (ROE) | -35444.23% | -301.40% | -319.56% | -78.67% | -56.73% |
| Return on Capital Employed (ROCE) | -7388.81% | -401.27% | -318.58% | -73.61% | -66.31% |
| Return on Invested Capital (ROIC) | -4159.84% | -276.81% | -303.73% | -72.72% | -56.40% |
| Return on Tangible Assets | -160.34% | -105.13% | -145.20% | -58.15% | -48.09% |
| Earnings Yield | -10.46% | -31.95% | -62.23% | -50.55% | -49.82% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.11 | -0.02 | -0.24 | -0.31 | -0.33 |
| Free Cash Flow Per Share | -0.11 | -0.02 | -0.24 | -0.31 | -0.33 |
| Dividend Paid and CapEx Coverage Ratio | -611.76 | -80.32 | 0.00 | 0.00 | -989.25 |
| Capital Expenditure Coverage Ratio | -611.76 | -80.32 | 0.00 | 0.00 | -989.25 |
| Operating Cash Flow Coverage Ratio | -28.17 | -11.50 | -50.29 | -43.81 | -11.91 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.30% | -3.32% | -43.70% | -52.50% | -34.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.31 | -3.16 | -1.61 | -1.98 | -2.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3389.26 | 9.43 | 5.14 | 1.56 | 1.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.70 | -30.08 | -2.29 | -1.90 | -2.91 |
| Price-to-Operating Cash Flow Ratio | -13.72 | -30.45 | -2.29 | -1.90 | -2.91 |
| Price-to-Earnings Growth (PEG) Ratio | -0.20 | 0.07 | -0.12 | 0.05 | 0.18 |
| Enterprise Value Multiple | -9.50 | -2.02 | -1.60 | -0.83 | -0.23 |
| Enterprise Value | 172.69M | 33.51M | 27.49M | 12.70M | 6.18M |
| EV to EBITDA | -9.50 | -2.02 | -1.60 | -0.83 | -0.23 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -13.42 | -27.15 | -2.21 | -0.79 | -0.38 |
| EV to Operating Cash Flow | -13.44 | -27.48 | -2.21 | -0.79 | -0.38 |
| Tangible Book Value Per Share | 0.00 | 0.07 | 0.11 | 0.39 | 0.84 |
| Shareholders’ Equity Per Share | 0.00 | 0.07 | 0.11 | 0.39 | 0.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.29 | -0.03 | 0.00 | 0.12 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.16 | -0.22 | -0.35 | -0.30 | -0.48 |
| Tax Burden | 1.00 | 0.71 | 1.03 | 1.00 | 0.88 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.70 | 0.13 | 0.89 | 1.27 | 0.93 |
Currency in USD